Johnson & Johnson

10/19/2025 | Press release | Distributed by Public on 10/19/2025 08:37

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

We're sorry, but there is no page on the site that matches your entry. It is possible you typed the address incorrectly, or the page may no longer exist. You may wish to try another entry or choose from the links below, which we hope will help you find what you are looking for.

If you believe that this page should exist, please send an email to [email protected] explaining the page you were trying to access.

Thanks for your patience, understanding, and help.

Johnson & Johnson published this content on October 19, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 19, 2025 at 14:37 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]